You may also like
Baxter Initiates Worldwide Voluntary Recall Of Select Lots Of 5 percent Dextrose Injection, USP And 0.9 percent Sodium Chloride Injection, USP Intravenous (IV) Solutions
Baxter International Inc. announced today it has initiated a voluntary recall to the hospital/user level of one lot of 5 percent Dextrose Injection, USP and four lots of 0.9 percent Sodium Chloride Injection, USP due to particulate matter found in the solutions. Injecting a product containing particulate matter may result in blockages of blood vessels, which can result in stroke, heart attack or damage to other organs such as the kidney or liver.
Drug, Devices, Technologies, and Techniques for Blood Management in Minimally Invasive and Conventional Cardiothoracic Surgery: A Consensus Statement From the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011
The objectives of this consensus conference were to evaluate the evidence for the efficacy and safety of perioperative drugs, technologies, and techniques in reducing allogeneic blood transfusion for adults undergoing cardiac surgery and to develop evidence-based recommendations for comprehensive perioperative blood management in cardiac surgery, with emphasis on minimally invasive cardiac surgery.
AVANT’s TP10 Complement Inhibitor Significantly Decreases Heart Attacks and Death in Men Following Cardiac Surgery
Results of Phase II Clinical Study of TP10 Presented at the American Heart Association Meeting in Orlando Use of an investigational therapeutic […]
